Dystrophin-deficient large animal models: Translational research and exon skipping

American Journal of Translational Research

Volumn 7, Issue 8, 2015, Pages 1314-1331

  Yu, Xinran ^a   Bao, Bo ^a   Echigoya, Yusuke ^a   Yokota, Toshifumi ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Canine X linked muscular dystrophy (CXMD); Duchenne muscular dystrophy (DMD); Exon skipping; Golden reliever muscular dystrophy (GRMD); Hypertrophic feline muscular dystrophy (HFMD); Porcine (pig) model

Indexed keywords

ALPHA SARCOGLYCAN; ALPHA7 INTEGRIN; BETA DYSTROGLYCAN; BORTEZOMIB; CYCLOOXYGENASE 2; DYSTROPHIN; EARLY GROWTH RESPONSE FACTOR 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8;

ANIMAL MODEL; CANINE MODEL; CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; ELECTROCARDIOGRAPHY; EXON; FIBROSIS; GENE DELETION; GENE EXPRESSION; HISTOLOGY; HUMAN; IMMUNE RESPONSE; KYPHOSIS; MUSCLE ATROPHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE C FOS; POINT MUTATION; PORCINE MODEL; PROTEIN EXPRESSION; RESPIRATORY FAILURE; REVIEW; STOP CODON; TRANSLATIONAL RESEARCH;

EID: 84941203488     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Duchenne. The Pathology of Paralysis with Muscular Degeneration (Paralysie Myosclerotique), or Paralysis with Apparent Hypertrophy. Br Med J 1867; 2: 541-542.
2. Moser H. Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet 1984; 66: 17-40.
3. Flanigan KM. Duchenne and Becker Muscular Dystrophies. Neurol Clin 2014; 32: 671-688.
4. Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Barisic N, Brabec P, Lahdetie J, Walter MC, Schreiber- Katz O, Karcagi V, Garami M, Viswanathan V, Bayat F, Buccella F, Kimura E, Koeks Z, van den Bergen JC, Rodrigues M, Roxburgh R, Lusakowska A, Kostera-Pruszczyk A, Zimowski J, Santos R, Neagu E, Artemieva S, Rasic VM, Vojinovic D, Posada M, Bloetzer C, Jeannet PY, Joncourt F, Diaz-Manera J, Gallardo E, Karaduman AA, Topaloglu H, Sherif RE, Stringer A, Shatillo AV, Martin AS, Peay HL, Bellgard MI, Kirschner J, Flanigan KM, Straub V, Bushby K, Verschuuren J, Aartsma-Rus A, Beroud C and Lochmuller H. The TREAT-NMD DMD Global database: Analysis of More Than 7000 Duchenne Muscular Dystrophy Mutations. Hum Mutat 2015; 36: 395-402.
5. Goemans N and Buyse G. Current treatment and management of dystrophinopathies. Curr Treat Options Neurol 2014; 16: 287.
6. Kornegay JN, Spurney CF, Nghiem PP, Brinkmeyer- Langford CL, Hoffman EP and Nagaraju K. Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J 2014; 55: 119-149.
7. Jarmin S, Kymalainen H, Popplewell L and Dickson G. New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol Ther 2014; 14: 209- 230.
8. Lu QL, Cirak S and Partridge T. What Can We Learn From Clinical Trials of Exon Skipping for DMD? Mol Ther Nucleic Acids 2014; 3: e152.
9. Willmann R, Possekel S, Dubach-Powell J, Meier T and Ruegg MA. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 2009; 19: 241-249.
10. Nakamura A and Takeda S. Mammalian models of Duchenne Muscular Dystrophy: pathological characteristics and therapeutic applications. J Biomed Biotechnol 2011; 2011: 184393.
11. Nakamura K, Fujii W, Tsuboi M, Tanihata J, Teramoto N, Takeuchi S, Naito K, Yamanouchi K and Nishihara M. Generation of muscular dystrophy model rats with a CRISPR/Cas system. Sci Rep 2014; 4: 5635.
12. Larcher T, Lafoux A, Tesson L, Remy S, Thepenier V, Francois V, Le Guiner C, Goubin H, Dutilleul M, Guigand L, Toumaniantz G, De Cian A, Boix C, Renaud JB, Cherel Y, Giovannangeli C, Concordet JP, Anegon I and Huchet C. Characterization of Dystrophin Deficient Rats: A New Model for Duchenne Muscular Dystrophy. PLoS One 2014; 9: e110371.
13. Klymiuk N, Blutke A, Graf A, Krause S, Burkhardt K, Wuensch A, Krebs S, Kessler B, Zakhartchenko V, Kurome M, Kemter E, Nagashima H, Schoser B, Herbach N, Blum H, Wanke R, Aartsma-Rus A, Thirion C, Lochmuller H, Walter MC and Wolf E. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. Hum Mol Genet 2013; 22: 4368- 4382.
14. Hollinger K, Yang CX, Montz RE, Nonneman D, Ross JW and Selsby JT. Dystrophin insufficiency causes selective muscle histopathology and loss of dystrophin-glycoprotein complex assembly in pig skeletal muscle. FASEB J 2014; 28: 1600-9.
15. Caskey CT, Nussbaum RL, Cohan LC and Pollack L. Sporadic occurrence of Duchenne muscular dystrophy: evidence for new mutation. Clin Genet 1980; 18: 329-341.
16. Barbujani G, Russo A, Danieli GA, Spiegler AW, Borkowska J and Petrusewicz IH. Segregation analysis of 1885 DMD families: significant departure from the expected proportion of sporadic cases. Hum Genet 1990; 84: 522-526.
17. Ito D, Kitagawa M, Jeffery N, Okada M, Yoshida M, Kobayashi M, Nakamura A and Watari T. Dystrophin-deficient muscular dystrophy in an Alaskan malamute. Vet Rec 2011; 169: 127.
18. Shelton GD, Liu LA, Guo LT, Smith GK, Christiansen JS, Thomas WB, Smith MO, Kline KL, March PA, Flegel T and E. E. Muscular Dystrophy in Female Dogs. J Vet Intern Med 2001; 15: 240-244.
19. van Ham LML, Desmidt M, Tshamala M, Hoorens JK and Mattheeuws DRG. Canine X-linked muscular-dystrophy in belgian groenendaeler shepherds. J Am Anim Hosp Assoc 1993; 29: 570-574.
20. Walmsley GL, Arechavala-Gomeza V, Fernandez- Fuente M, Burke MM, Nagel N, Holder A, Stanley R, Chandler K, Marks SL, Muntoni F, Shelton GD and Piercy RJ. A duchenne muscular dystrophy gene hot spot mutation in dystrophin- deficient cavalier king charles spaniels is amenable to exon 51 skipping. PLoS One 2010; 5: e8647.
21. Kornegay JN, Bogan JR, Bogan DJ, Childers MK, Li J, Nghiem P, Detwiler DA, Larsen CA, Grange RW, Bhavaraju-Sanka RK, Tou S, Keene BP, Howard JF Jr, Wang J, Fan Z, Schatzberg SJ, Styner MA, Flanigan KM, Xiao X and Hoffman EP. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome 2012; 23: 85-108.
22. Schatzberg SJ, Olby NJ, Breen M, Anderson LV, Langford CF, Dickens HF, Wilton SD, Zeiss CJ, Binns MM, Kornegay JN, Morris GE and Sharp NJ. Molecular analysis of a spontaneous dystrophin 'knockout' dog. Neuromuscul Disord 1999; 9: 289-295.
23. Sharp NJ, Kornegay JN, Van Camp SD, Herbstreith MH, Secore SL, Kettle S, Hung WY, Constantinou CD, Dykstra MJ, Roses AD and et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1992; 13: 115-121.
24. Klarenbeek S, Gerritzen-Bruning MJ, Rozemuller AJ and van der Lugt JJ. Canine X-linked muscular dystrophy in a family of Grand Basset Griffon Vendeen dogs. J Comp Pathol 2007; 137: 249-252.
25. Wentink GH, van der Linde-Sipman JS, Meijer AEFH, Kamphuisen HAC, van Vorstenbosch CJAHV, Hartman WJHH. Myopathy with a possible recessive X-linked inheritance in a litter of Irish Terriers. Vet Pathol 1972; 9: 328- 349.
26. Atencia-Fernandez S, Shiel RE, Mooney CT and Nolan CM. Muscular dystrophy in the Japanese Spitz: an inversion disrupts the DMD and RPGR genes. Anim Genet 2015; 46: 175-84.
27. Shin JH, Greer B, Hakim CH, Zhou Z, Chung YC, Duan Y, He Z and Duan D. Quantitative phenotyping of Duchenne muscular dystrophy dogs by comprehensive gait analysis and overnight activity monitoring. PLoS One 2013; 8: e59875.
28. Bergman RL, Inzana KD, Monroe WE, Shell LG, Liu LA, Engvall E and Shelton GD. Dystrophindeficient muscular dystrophy in a Labrador retriever. J Am Anim Hosp Assoc 2002; 38: 255- 261.
29. Baroncelli AB, Abellonio F, Pagano TB, Esposito I, Peirone B, Papparella S and Paciello O. Muscular dystrophy in a dog resembling human becker muscular dystrophy. J Comp Pathol 2014; 150: 429-433.
30. Giannasi C, Tappin SW, Guo LT, Shelton GD and Palus V. Dystrophin-deficient muscular dystrophy in two lurcher siblings. J Small Anim Pract 2015; [Epub ahead of print].
31. Beltran E, Shelton GD, Guo LT, Dennis R, Sanchez- Masian D, Robinson D and De Risio L. Dystrophin-deficient muscular dystrophy in a Norfolk terrier. J Small Anim Pract 2015; 56: 351-4.
32. Wieczorek LA, Garosi LS and Shelton GD. Dystrophin- deficient muscular dystrophy in an old English sheepdog. Vet Rec 2006; 158: 270- 273.
33. Smith BF, Yue Y, Woods PR, Kornegay JN, Shin JH, Williams RR and Duan D. An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab Invest 2011; 91: 216-231.
34. Wetterman CA, Harkin KR, Cash WC, Nietfield JC and Shelton GD. Hypertrophic muscular dystrophy in a young dog. J Am Vet Med Assoc 2000; 216: 878-881, 864.
35. Baltzer WI, Calise DV, Levine JM, Shelton GD, Edwards JF and Steiner JM. Dystrophin-deficient muscular dystrophy in a Weimaraner. J Am Anim Hosp Assoc 2007; 43: 227-232.
36. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T and Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 2014; 24: 482-491.
37. Shimatsu Y, Katagiri K, Furuta T, Nakura M, Tanioka Y, Yuasa K, Tomohiro M, Kornegay JN, Nonaka I and Takeda S. Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 2003; 52: 93-97.
38. Passamano L, Taglia A, Palladino A, Viggiano E, D'Ambrosio P, Scutifero M, Rosaria Cecio M, Torre VFDEL, Picillo E, Paciello O, Piluso G, Nigro G and Politano L. Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol 2012; 31: 121-125.
39. Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, Sampson JB, Mendell JR, Wall C, King WM, Pestronk A, Florence JM, Connolly AM, Mathews KD, Stephan CM, Laubenthal KS, Wong BL, Morehart PJ, Meyer A, Finkel RS, Bonnemann CG, Medne L, Day JW, Dalton JC, Margolis MK, Hinton VJ and Weiss RB. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 2009; 30: 1657-1666.
40. Nguyen F, Cherel Y, Guigand L, Goubault-Leroux I and Wyers M. Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies. J Comp Pathol 2002; 126: 100-108.
41. Passerini L, Bernasconi P, Baggi F, Confalonieri P, Cozzi F, Cornelio F and Mantegazza R. Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. Neuromuscul Disord 2002; 12: 828-835.
42. Valentine BA, Cooper BJ, de Lahunta A, O'Quinn R and Blue JT. Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci 1988; 88: 69-81.
43. Spurney CF. Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 2011; 44: 8-19.
44. Valentine BA, Cummings JF and Cooper BJ. Development of Duchenne-type cardiomyopathy. Morphologic studies in a canine model. Am J Pathol 1989; 135: 671-678.
45. DeVanna JC, Kornegay JN, Bogan DJ, Bogan JR, Dow JL and Hawkins EC. Respiratory dysfunction in unsedated dogs with golden retriever muscular dystrophy. Neuromuscul Disord 2014; 24: 63-73.
46. Mead AF, Petrov M, Malik AS, Mitchell MA, Childers MK, Bogan JR, Seidner G, Kornegay JN and Stedman HH. Diaphragm remodeling and compensatory respiratory mechanics in a canine model of Duchenne muscular dystrophy. J Appl Physiol (1985) 2014; 116: 807- 815.
47. Kornegay JN, Bogan JR, Bogan DJ, Childers MK and Grange RW. Golden retriever muscular dystrophy (GRMD): Developing and maintaining a colony and physiological functional measurements. Methods Mol Biol 2011; 709: 105- 123.
48. Shimatsu Y, Yoshimura M, Yuasa K, Urasawa N, Tomohiro M, Nakura M, Tanigawa M, Nakamura A and Takeda S. Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 2005; 24: 145-154.
49. Yugeta N, Urasawa N, Fujii Y, Yoshimura M, Yuasa K, Wada MR, Nakura M, Shimatsu Y, Tomohiro M, Takahashi A, Machida N, Wakao Y, Nakamura A and Takeda S. Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies. BMC Cardiovasc Disord 2006; 6: 47.
50. Urasawa N, Wada MR, Machida N, Yuasa K, Shimatsu Y, Wakao Y, Yuasa S, Sano T, Nonaka I, Nakamura A and Takeda S. Selective vacuolar degeneration in dystrophin-deficient canine Purkinje fibers despite preservation of dystrophin- associated proteins with overexpression of Dp71. Circulation 2008; 117: 2437-2448.
51. Nakamura A, Kobayashi M, Kuraoka M, Yuasa K, Yugeta N, Okada T and Takeda S. Initial pulmonary respiration causes massive diaphragm damage and hyper-CKemia in Duchenne muscular dystrophy dog. Sci Rep 2013; 3: 2183.
52. Duan D. Duchenne muscular dystrophy gene therapy in the canine model. Hum Gene Ther Clin Dev 2015; 26: 57-69.
53. Yokota T, Pistilli E, Duddy W and Nagaraju K. Potential of oligonucleotide-mediated exonskipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 2007; 7: 831- 842.
54. Pramono ZA, Takeshima Y, Alimsardjono H, Ishii A, Takeda S and Matsuo M. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 1996; 226: 445-449.
55. Yokota T, Hoffman E and Takeda S. Antisense oligo-mediated multiple exon skipping in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 2011; 709: 299-312.
56. Vulin A, Barthelemy I, Goyenvalle A, Thibaud JL, Beley C, Griffith G, Benchaouir R, le Hir M, Unterfinger Y, Lorain S, Dreyfus P, Voit T, Carlier P, Blot S and Garcia L. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 2012; 20: 2120-2133.
57. Bish LT, Sleeper MM, Forbes SC, Wang B, Reynolds C, Singletary GE, Trafny D, Morine KJ, Sanmiguel J, Cecchini S, Virag T, Vulin A, Beley C, Bogan J, Wilson JM, Vandenborne K, Kornegay JN, Walter GA, Kotin RM, Garcia L and Sweeney HL. Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther 2012; 20: 580-589.
58. Su JB, Cazorla O, Blot S, Blanchard-Gutton N, Ait Mou Y, Barthelemy I, Sambin L, Sampedra no CC, Gouni V, Unterfinger Y, Aguilar P, Thibaud JL, Bize A, Pouchelon JL, Dabire H, Ghaleh B, Berdeaux A, Chetboul V, Lacampagne A and Hittinger L. Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy. Cardiovasc Res 2012; 95: 86-96.
59. Barbash IM, Cecchini S, Faranesh AZ, Virag T, Li L, Yang Y, Hoyt RF, Kornegay JN, Bogan JR, Garcia L, Lederman RJ and Kotin RM. MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Gene Ther 2013; 20: 274-282.
60. Wuebbles RD, Sarathy A, Kornegay JN and Burkin DJ. Levels of alpha7 integrin and lamininalpha2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy. Dis Model Mech 2013; 6: 1175-1184.
61. Araujo KP, Bonuccelli G, Duarte CN, Gaiad TP, Moreira DF, Feder D, Belizario JE, Miglino MA, Lisanti MP and Ambrosio CE. Bortezomib (PS- 341) treatment decreases inflammation and partially rescues the expression of the dystrophin- glycoprotein complex in GRMD dogs. PLoS One 2013; 8: e61367.
62. Saito T, Nakamura A, Aoki Y, Yokota T, Okada T, Osawa M and Takeda S. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 2010; 5: e12239.
63. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S and Hoffman E. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009; 65: 667-676.
64. Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP and Takeda S. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 2012; 22: 306-315.
65. Hayashita-Kinoh H, Yugeta N, Okada H, Nitahara- Kasahara Y, Chiyo T, Okada T and Takeda S. Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance. Mol Ther 2015; 23: 627-37.
66. Sakamoto M, Yuasa K, Yoshimura M, Yokota T, Ikemoto T, Suzuki M, Dickson G, Miyagoe-Suzuki Y and Takeda S. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 2002; 293: 1265-1272.
67. Ambrosio CE, Valadares MC, Zucconi E, Cabral R, Pearson PL, Gaiad TP, Canovas M, Vainzof M, Miglino MA and Zatz M. Ringo, a Golden Retriever Muscular Dystrophy (GRMD) dog with absent dystrophin but normal strength. Neuromuscul Disord 2008; 18: 892-893.
68. Ambrosio CE, Fadel L, Gaiad TP, Martins DS, Araujo KP, Zucconi E, Brolio MP, Giglio RF, Morini AC, Jazedje T, Froes TR, Feitosa ML, Valadares MC, Beltrao-Braga PC, Meirelles FV and Miglino MA. Identification of three distinguishable phenotypes in golden retriever muscular dystrophy. Genet Mol Res 2009; 8: 389- 396.
69. Bello L, Kesari A, Gordish-Dressman H, Cnaan A, Morgenroth LP, Punetha J, Duong T, Henricson EK, Pegoraro E, McDonald CM and Hoffman EP. Genetic modifiers of ambulation in the CINRG duchenne natural history study. Ann Neurol 2015; 77: 684-96.
70. Miyazato LG, Moraes JR, Beretta DC and Kornegay JN. Muscular dystrophy in dogs: does the crossing of breeds influence disease phenotype? Vet Pathol 2011; 48: 655-662.
71. Jang G, Kim MK and Lee BC. Current status and applications of somatic cell nuclear transfer in dogs. Theriogenology 2010; 74: 1311- 1320.
72. Fan N and Lai L. Genetically modified pig models for human diseases. J Genet Genomics 2013; 40: 67-73.
73. Gun G and Kues WA. Current progress of genetically engineered pig models for biomedical research. Biores Open Access 2014; 3: 255- 264.
74. Lelovas PP, Kostomitsopoulos NG and Xanthos TT. A comparative anatomic and physiologic overview of the porcine heart. J Am Assoc Lab Anim Sci 2014; 53: 432-438.
75. Nonneman DJ, Brown-Brandl T, Jones SA, Wiedmann RT and Rohrer GA. A defect in dystrophin causes a novel porcine stress syndrome. BMC Genomics 2012; 13: 233.
76. Kurome M, Geistlinger L, Kessler B, Zakhartchenko V, Klymiuk N, Wuensch A, Richter A, Baehr A, Kraehe K, Burkhardt K, Flisikowski K, Flisikowska T, Merkl C, Landmann M, Durkovic M, Tschukes A, Kraner S, Schindelhauer D, Petri T, Kind A, Nagashima H, Schnieke A, Zimmer R and Wolf E. Factors influencing the efficiency of generating genetically engineered pigs by nuclear transfer: multi-factorial analysis of a large data set. BMC Biotechnol 2013; 13: 43.
77. Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, Kneile K, Dunn DM, Duval B, Aoyagi A, Hamil C, Mahmoud M, Roush K, Bird L, Rankin C, Lilly H, Street N, Chandrasekar R and Weiss RB. Evidencebased path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012; 71: 304-313.
78. Zhao J, Whyte J and Prather RS. Effect of epigenetic regulation during swine embryogenesis and on cloning by nuclear transfer. Cell Tissue Res 2010; 341: 13-21.
79. Cho SK, Kim JH, Park JY, Choi YJ, Bang JI, Hwang KC, Cho EJ, Sohn SH, Uhm SJ, Koo DB, Lee KK, Kim T and Kim JH. Serial cloning of pigs by somatic cell nuclear transfer: restoration of phenotypic normality during serial cloning. Dev Dyn 2007; 236: 3369-3382.
80. Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ and van Deutekom JC. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12 Suppl 1: S71-77.
81. Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M, Morgan JE, van Deutekom JC, Wilton SD, Dickson G and Muntoni F. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin premRNA splicing in human muscle. Hum Gene Ther 2007; 18: 798-810.
82. Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T and Takeda S. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 2010; 18: 1995- 2005.
83. Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T and Takeda S. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-alpha2 chain-null congenital muscular dystrophy mice. Hum Mol Genet 2013; 22: 4914-4928.
84. Beroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, Moizard MP, Voelckel MA, Calemard LM, Boisseau P, Blayau M, Philippe C, Cossee M, Pages M, Rivier F, Danos O, Garcia L and Claustres M. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 2007; 28: 196-202.
85. Nakamura A, Yoshida K, Fukushima K, Ueda H, Urasawa N, Koyama J, Yazaki Y, Yazaki M, Sakai T, Haruta S, Takeda S and Ikeda S. Follow- up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J Clin Neurosci 2008; 15: 757-763.
86. Yokota T, Takeda S, Lu QL, Partridge TA, Nakamura A and Hoffman EP. A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 2009; 66: 32-38.
87. Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T and Takeda S. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 2012; 109: 13763-13768.
88. Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, Tanihata J, Nakamura A, Nagaraju K and Yokota T. Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 2015; 4: e225.
89. Aoki Y, Yokota T and Wood MJ. Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. Biomed Res Int 2013; 2013: 402369.
90. Echigoya Y and Yokota T. Skipping Multiple Exons of Dystrophin Transcripts Using Cocktail Antisense Oligonucleotides. Nucleic Acid Ther 2014; 24: 57-68.
91. Carpenter JL, Hoffman EP, Romanul FC, Kunkel LM, Rosales RK, Ma NS, Dasbach JJ, Rae JF, Moore FM, McAfee MB and et al. Feline muscular dystrophy with dystrophin deficiency. Am J Pathol 1989; 135: 909-919.
92. Winand NJ, Edwards M, Pradhan D, Berian CA and Cooper BJ. Deletion of the dystrophin muscle promoter in feline muscular dystrophy. Neuromuscul Disord 1994; 4: 433-445.
93. Gambino AN, Mouser PJ, Shelton GD and Winand NJ. Emergent presentation of a cat with dystrophin-deficient muscular dystrophy. J Am Anim Hosp Assoc 2014; 50: 130-135.
94. Gaschen FP, Hoffman EP, Gorospe JR, Uhl EW, Senior DF, Cardinet GH 3rd and Pearce LK. Dystrophin deficiency causes lethal muscle hypertrophy in cats. J Neurol Sci 1992; 110: 149- 159.
95. Gaschen F and Burgunder JM. Changes of skeletal muscle in young dystrophin-deficient cats: a morphological and morphometric study. Acta Neuropathol 2001; 101: 591-600.
96. Seiler G, Welle M, Busato A, Lin S and Gaschen FP. Mast cell proliferation and alterations in bFGF amount and localization are involved in the response of muscle to dystrophin deficiency in hypertrophic feline dystrophy. Neuromuscul Disord 2001; 11: 56-71.
97. Radojevic V, Oppliger C, Gaschen F and Burgunder JM. Restoration of dystrophin expression in cultured hybrid myotubes. Neuropathol Appl Neurobiol 2002; 28: 397-409.
98. Howard J, Jaggy A, Busato A and Gaschen F. Electrodiagnostic evaluation in feline hypertrophic muscular dystrophy. Vet J 2004; 168: 87- 92.
99. Chetboul V, Blot S, Sampedrano CC, Thibaud JL, Granger N, Tissier R, Bruneval P, Gaschen F, Gouni V, Nicolle AP and Pouchelon JL. Tissue Doppler imaging for detection of radial and longitudinal myocardial dysfunction in a family of cats affected by dystrophin-deficient hypertrophic muscular dystrophy. J Vet Intern Med 2006; 20: 640-647.
100. Gaschen L, Lang J, Lin S, Ade-Damilano M, Busato A, Lombard CW and Gaschen FP. Cardiomyopathy in dystrophin-deficient hypertrophic feline muscular dystrophy. J Vet Intern Med 1999; 13: 346-356.
101. Gaschen F, Gaschen L, Seiler G, Welle M, Jaunin VB, Jmaa DG, Neiger-Aeschbacher G and Ade-Damilano M. Lethal peracute rhabdomyolysis associated with stress and general anesthesia in three dystrophin-deficient cats. Vet Pathol 1998; 35: 117-123.
102. Segura LG, Lorenz JD, Weingarten TN, Scavonetto F, Bojanic K, Selcen D and Sprung J. Anesthesia and Duchenne or Becker muscular dystrophy: review of 117 anesthetic exposures. Paediatr Anaesth 2013; 23: 855-864.
103. Valentine BA, Cooper BJ, Cummings JF and deLahunta A. Progressive muscular dystrophy in a golden retriever dog: light microscope and ultrastructural features at 4 and 8 months. Acta Neuropathol 1986; 71: 301-310.
104. Barthelemy I, Pinto-Mariz F, Yada E, Desquilbet L, Savino W, Silva-Barbosa SD, Faussat AM, Mouly V, Voit T, Blot S and Butler-Browne G. Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy. Dis Model Mech 2014; 7: 1253-1261.
105. Kornegay JN, Bogan DJ, Bogan JR, Childers MK, Cundiff DD, Petroski GF and Schueler RO. Contraction force generated by tarsal joint flexion and extension in dogs with golden retriever muscular dystrophy. J Neurol Sci 1999; 166: 115-121.
106. Kornegay JN, Cundiff DD, Bogan DJ, Bogan JR and Okamura CS. The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy. Neuromuscul Disord 2003; 13: 493-500.
107. Moise NS, Valentine BA, Brown CA, Erb HN, Beck KA, Cooper BJ and Gilmour RF. Duchenne's cardiomyopathy in a canine model: electrocardiographic and echocardiographic studies. J Am Coll Cardiol 1991; 17: 812-820.
108. Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, Kornegay JN and Metzger JM. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010; 120: 1140-1150.